The vasoactive intestinal peptide (VIP) α-helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/pituitary adenylate cyclase-activating peptide 1 receptor: Photoaffinity, molecular modeling, and dynamics

Molecular Endocrinology

Volumn 22, Issue 1, 2008, Pages 147-155

  Ceraudo, Emilie ^a   Murail, Samuel ^b   Tan, Yossan Var ^a   Lacapère, Jean Jacques ^a   Neumann, Jean Michel ^b   Couvineau, Alain ^a   Laburthe, Marc ^a  

^a INSERM   (France)

^b DIF   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR 1; NEUROPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BETA SHEET; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CHO CELL; CONTROLLED STUDY; DISULFIDE BOND; ECTODOMAIN; HORMONE RECEPTOR INTERACTION; MOLECULAR DYNAMICS; MOLECULAR MODEL; NEUROTRANSMITTER RELEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PATHOPHYSIOLOGY; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS; SUBSTITUTION REACTION; SUSHI DOMAIN; THREE DIMENSIONAL IMAGING;

ANIMALS; BINDING SITES; CHO CELLS; COMPUTER SIMULATION; CRICETINAE; CRICETULUS; HUMANS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; VASOACTIVE INTESTINAL PEPTIDE;

EID: 38049086728     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2007-0361     Document Type: Article

References (32)

1. Sherwood NM, Krueckl SL, McRory, JE 2000 The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 21:619-670
2. Delgado MD, Pozo D, Ganea D 2004 The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 56:249-290
3. Vaudry H, Laburthe M 2006 VIP, PACAP and related peptides: from gene to therapy. Ann NY Acad Sci 1070:1-633
4. Gomariz RP, Juarranz Y, Abad C, Arranz A, Leceta J, Martinez C 2006 VIP-PACAP system in immunity: new insights for multitarget therapy. Ann NY Acad Sci 1070:51-74
5. Gozes I., Fridkinb M, Hill JM, Brenneman DE 1999 Pharmaceutical VIP: prospects and problems. Curr Med Chem 6:1019-1034
6. Laburthe M, Couvineau A, Tan V 2007 Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 28:1631-1639
7. Laburthe M, Couvineau A, Marie JC 2002 VPAC receptors for VIP and PACAP. Receptors Channels 8:137-153
8. Tan YV, Couvineau A, Van Rampelbergh J, Laburthe M 2003 Photoaffinity labeling demonstrates physical contact between vasoactive intestinal peptide and the N-terminal ectodomain of the human VPAC1 receptor. J Biol Chem 278:36531-36536
9. Tan YV, Couvineau A, Laburthe M 2004 Diffuse pharmacophoric domains of vasoactive intestinal peptide (VIP) and further insights into the interaction of VIP with the N-terminal ectodomain of human VPAC1 receptor by photoaffinity labeling with [Bpa6]-VIP. J Biol Chem 279:38889-38894
10. Tan YV, Couvineau A, Murail S, Ceraudo E, Neumann JM, Lacapère JJ, Laburthe M 2006 Peptide agonist docking in the N-terminal ectodomain of a class II G protein-coupled receptor, the VPAC1 receptor. Photoaffinity, NMR, and molecular modeling. J Biol Chem 281:12792-12798
11. Grace CR, Perrin MH, DiGruccio MR, Miller CL, Rivier JE, Vale WW, Riek R 2004 NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. Proc Natl Acad Sci USA 101:12836-12841
12. Schwarzenbacher R, Zeth K, Diederichs K, Gries A, Kostner GM, Laggner P, Prassl R 1999 Crystal structure of human β2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 18:6228-6239
13. Nicole P, Lins L, Rouyer-Fessard C, Drouot C, Fulcrand P, Thomas A, Couvineau A, Martinez J, Brasseur R, Laburthe M 2000 Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide. J Biol Chem 275:24003-24012
14. Couvineau A, Fabre C, Gaudin P, Maoret J, Laburthe M 1996 Mutagenesis of N-glycosylation sites in the human vasoactive intestinal peptide 1 receptor. Evidence that asparagine 58 or 69 is crucial for correct delivery of the receptor to plasma membrane. Biochemistry 35:1745-1752
15. Sankaranarayanan K, Ramasamy P 2006 Growth of benzophenone single crystals from solution: a novel approach with 100% solute-crystal conversion efficiency. Cryst Res Technol 41:225-230
16. Wray V, Nokihara K, Naruse S, Ando E, Kakoschke C, Wei M 1995 Synthesis, solution structure and biological action of PACAP-related peptide. Biomed Pept Proteins Nucleic Acids 1:77-82
17. Dong M, Miller LJ 2006 Use of photoaffinity labeling to understand the molecular basis of ligand binding to the secretin receptor. Ann NY Acad Sci 1070:248-264
18. Gensure RC, Shimizu N, Tsang J, Gardella TJ 2003 Identification of a contact site for residue 19 of parathyroid hormone (PTH) and PTH-related protein analogs in trans-membrane domain two of the type 1 PTH receptor. Mol Endocrinol 17:2647-2658
19. Grace CR, Perrin MH, Gulyas J, Digruccio MR, Cantle JP, Rivier JE, Vale WW, Riek R 2007 Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand. Proc Natl Acad Sci USA 104:4858-4863
20. Sun C, Song D, Davis-Taber RA, Barrett LW, Scott VE, Richardson PL, Pereda-Lopez A, Uchic ME, Solomon LR, Lake MR, Walter KA, Hajduk PJ, Olejniczak ET 2007 Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS. Proc Natl Acad Sci USA 104:7875-7880
21. Hoare SRJ 2005 Mechanisms of peptide and nonpeptide ligand binding to class B G-protein-coupled receptors. Drug Discov Today 10:417-427
22. Couvineau A, Rouyer-Fessard C, Fournier A, St Pierre S, Pipkorn R, Laburthe M 1984 Structural requirements for VIP interaction with specific receptors in human and rat intestinal membranes: effect of nine partial sequences. Biochem Biophys Res Commun 121:493-498
23. Langer I, Vertongen P, Perret J, Cnudde J, Gregoire F, De Neef P, Robberecht P, Waelbroeck M 2002 VPAC(1) receptors have different agonist efficacy profiles on membrane and intact cells. Cell Signal 14:689-694
24. Solano RM, Langer I, Perret J, Vertongen P, Juarranz MG, Robberecht P, Waelbroeck M 2001 Two basic residues of the h-VPAC1 receptor second transmembrane helix are essential for ligand binding and signal transduction. J Biol Chem 276:1084-1088
25. Gaudin P, Maoret J, Couvineau A, Rouyer-Fessard C, Laburthe M 1998 Constitutive activation of the human vasoactive intestinal peptide 1 receptor, a member of the new class II family of G protein-coupled receptors. J Biol Chem 273:4990-4996
26. Couvineau A, Lacapère JJ, Tan YV, Rouyer-Fessard C, Nicole P, Laburthe M 2003 Identification of cytoplasmic domains of hVPAC1 receptor required for activation of adenylyl cyclase. Crucial role of two charged amino acids strictly conserved in class II G protein-coupled receptors. J Biol Chem 278:24759-24766
27. Pearson WR, Lipman DJ 1988 Improved tools for biological sequence comparison. Proc Natl Acad Sci USA 85:2444-2448
28. Lins L, Couvineau A, Rouyer-Fessard C, Nicole P, Maoret J, Benhamed M, Brasseur R, Thomas A, Laburthe M 2001 The human VPAC1 receptor: three-dimensional model and mutagenesis of the N-terminal domain. J Biol Chem 276:10153-10160
29. Dominguez C, Boelens R, Bonvin AMJJ 2003 HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. J Am Chem Soc 125:1731-1737
30. Humphrey W, Dalke A, Schulten K 1996 VMD: visual molecular dynamics. J Mol Graphics 14:33-38
31. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid V, Villa E, Chipot C, Skeel R D, Kale L, Schulten K 2005 Scalable molecular dynamics with NAMD. J Comput Chem 26:1781-1802
32. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M 1983 CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 4:187-217